Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, DNTH, CGON, ORKA, ORKA, and represent 57.48% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: CATX (+$11M), ELVN (+$10M), Aktis Oncology (+$8.4M), VIR (+$6.3M), PVLA (+$6.3M), HUM (+$5.9M), DXCM (+$5.7M), ORKA, TENX, RGEN.
- Started 28 new stock positions in AVR, BBIO, TEM, ABUS, TRVI, BBOT, Satellos Bioscience, GPCR, ODD, PTON.
- Reduced shares in these 10 stocks: IMUX (-$39M), CGON (-$12M), , , TEVA (-$7.6M), , PFE (-$5.1M), DHR, TMO, NVO.
- Sold out of its positions in ACHC, A, ALNY, COR, CI, DHR, HQY, INSM, ITGR, IQV. MCK, NVO, PFE, TMO, WAT.
- Avidity Partners Management was a net seller of stock by $-37M.
- Avidity Partners Management has $936M in assets under management (AUM), dropping by 169.89%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 91 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 19.7 | $185M | 2.1M | 87.80 |
|
|
| Dianthus Therapeutics (DNTH) | 18.9 | $177M | 2.1M | 83.92 |
|
|
| Cg Oncology (CGON) | 9.3 | $87M | -12% | 1.3M | 67.68 |
|
| Oruka Therapeutics (ORKA) | 5.6 | $52M | +15% | 760k | 68.41 |
|
| Oruka Therapeutics (ORKA) | 4.0 | $37M | +15% | 760k | 49.05 |
|
| Jade Biosciences Com New (JBIO) | 3.7 | $34M | 1.4M | 24.40 |
|
|
| Perspective Therapeutics Com New (CATX) | 2.7 | $25M | +88% | 6.0M | 4.17 |
|
| Perspective Therapeutics Com New (CATX) | 2.5 | $24M | +88% | 6.0M | 3.90 |
|
| Jade Biosciences Com New (JBIO) | 2.1 | $20M | 1.4M | 14.05 |
|
|
| Enliven Therapeutics (ELVN) | 1.8 | $17M | +185% | 400k | 41.23 |
|
| Enliven Therapeutics (ELVN) | 1.7 | $16M | +185% | 400k | 39.20 |
|
| Teva Pharmaceutical Industries (TEVA) | 1.4 | $14M | -52% | 450k | 30.12 |
|
| Context Therapeutics (CNTX) | 1.4 | $13M | -9% | 5.0M | 2.62 |
|
| Context Therapeutics (CNTX) | 1.3 | $12M | -9% | 5.0M | 2.36 |
|
| Repligen Corporation (RGEN) | 1.0 | $9.2M | +54% | 78k | 118.31 |
|
| Repligen Corporation (RGEN) | 1.0 | $9.2M | +54% | 78k | 117.82 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.0 | $9.0M | +262% | 70k | 128.32 |
|
| Aktis Oncology | 0.9 | $8.8M | NEW | 469k | 18.75 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.9 | $8.7M | +262% | 70k | 124.65 |
|
| Medtronic SHS (MDT) | 0.9 | $8.7M | -7% | 100k | 86.65 |
|
| Vir Biotechnology (VIR) | 0.9 | $8.5M | NEW | 950k | 8.96 |
|
| Aktis Oncology | 0.9 | $8.4M | NEW | 469k | 17.89 |
|
| Medtronic SHS (MDT) | 0.9 | $8.1M | -7% | 100k | 80.97 |
|
| Immunic (IMUX) | 0.8 | $7.4M | -85% | 6.7M | 1.11 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.7 | $7.0M | -52% | 200k | 35.07 |
|
| Immunic (IMUX) | 0.7 | $6.4M | -85% | 670k | 9.62 |
|
| Vir Biotechnology (VIR) | 0.7 | $6.3M | NEW | 619k | 10.21 |
|
| Dex (DXCM) | 0.6 | $6.0M | NEW | 100k | 59.55 |
|
| Humana (HUM) | 0.6 | $5.9M | NEW | 25k | 236.44 |
|
| Dex (DXCM) | 0.6 | $5.7M | NEW | 90k | 62.80 |
|
| Encompass Health Corp (EHC) | 0.4 | $4.2M | +32% | 42k | 100.00 |
|
| Encompass Health Corp (EHC) | 0.4 | $4.1M | +32% | 42k | 96.73 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.4 | $3.9M | +244% | 464k | 8.31 |
|
| Boston Scientific Corporation (BSX) | 0.4 | $3.8M | -47% | 60k | 62.75 |
|
| Tempus Ai Cl A (TEM) | 0.4 | $3.6M | NEW | 65k | 55.48 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $3.5M | NEW | 266k | 13.11 |
|
| Boston Scientific Corporation (BSX) | 0.4 | $3.5M | -47% | 60k | 57.61 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $3.5M | NEW | 216k | 15.99 |
|
| Satellos Bioscience | 0.3 | $3.1M | NEW | 388k | 7.95 |
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $2.8M | +21% | 249k | 11.20 |
|
| Gilead Sciences (GILD) | 0.3 | $2.8M | NEW | 20k | 139.37 |
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $2.8M | +21% | 249k | 11.11 |
|
| Gilead Sciences (GILD) | 0.3 | $2.6M | NEW | 20k | 130.84 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.3 | $2.6M | +244% | 464k | 5.57 |
|
| Centene Corporation (CNC) | 0.2 | $2.3M | -41% | 70k | 32.74 |
|
| Satellos Bioscience | 0.2 | $2.2M | NEW | 388k | 5.63 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $2.0M | NEW | 48k | 41.45 |
|
| Scynexis Com New (SCYX) | 0.2 | $1.9M | 2.1M | 0.93 |
|
|
| Scynexis Com New (SCYX) | 0.2 | $1.9M | 2.1M | 0.92 |
|
|
| Icon SHS (ICLR) | 0.2 | $1.9M | -51% | 16k | 118.33 |
|
| Natera (NTRA) | 0.2 | $1.9M | -23% | 9.0k | 206.16 |
|
| Natera (NTRA) | 0.2 | $1.8M | -23% | 9.0k | 199.99 |
|
| Icon SHS (ICLR) | 0.2 | $1.8M | -51% | 16k | 110.66 |
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $1.7M | NEW | 115k | 15.19 |
|
| Kenvue (KVUE) | 0.2 | $1.7M | -57% | 100k | 17.24 |
|
| Insulet Corporation (PODD) | 0.2 | $1.7M | NEW | 10k | 172.14 |
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $1.7M | NEW | 115k | 14.63 |
|
| Charles River Laboratories (CRL) | 0.2 | $1.7M | NEW | 10k | 166.97 |
|
| Hims & Hers Health Com Cl A (HIMS) | 0.2 | $1.6M | NEW | 75k | 20.76 |
|
| Revolution Medicines (RVMD) | 0.2 | $1.5M | NEW | 15k | 97.25 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $1.4M | NEW | 30k | 48.20 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $1.4M | +36% | 30k | 46.52 |
|
| Hims & Hers Health Com Cl A (HIMS) | 0.1 | $1.4M | NEW | 50k | 27.17 |
|
| Genmab A/s -sp Sponsored Ads (GMAB) | 0.1 | $1.3M | -45% | 50k | 26.83 |
|
| Genmab A/s Sponsored Ads (GMAB) | 0.1 | $1.3M | -45% | 50k | 26.52 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $1.2M | +36% | 30k | 40.31 |
|
| Tempus Ai Cl A (TEM) | 0.1 | $1.1M | NEW | 25k | 45.22 |
|
| Abivax Sa- Sponsored Ads (ABVX) | 0.1 | $1.1M | NEW | 10k | 111.35 |
|
| Peloton Interactive Cl A Com (PTON) | 0.1 | $1.1M | NEW | 200k | 5.45 |
|
| UnitedHealth (UNH) | 0.1 | $1.0M | NEW | 3.8k | 270.59 |
|
| Intellia Therapeutics (NTLA) | 0.1 | $1.0M | NEW | 75k | 13.48 |
|
| Oddity Tech Shs Cl A (ODD) | 0.1 | $1.0M | NEW | 70k | 14.32 |
|
| Intellia Therapeutics (NTLA) | 0.1 | $962k | NEW | 75k | 12.82 |
|
| Oddity Tech Ltd-cl A Shs Cl A (ODD) | 0.1 | $937k | NEW | 70k | 13.38 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.1 | $932k | NEW | 50k | 18.64 |
|
| Anteris Technologies Global (AVR) | 0.1 | $923k | NEW | 150k | 6.15 |
|
| Abbott Laboratories (ABT) | 0.1 | $908k | NEW | 10k | 90.79 |
|
| Peloton Interactive Inc-a Cl A Com (PTON) | 0.1 | $858k | NEW | 200k | 4.29 |
|
| Anteris Technologies Global (AVR) | 0.1 | $833k | NEW | 150k | 5.55 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.1 | $819k | NEW | 50k | 16.38 |
|
| Bridgebio Pharma (BBIO) | 0.1 | $711k | NEW | 10k | 71.11 |
|
| Arbutus Biopharma (ABUS) | 0.1 | $563k | NEW | 125k | 4.50 |
|
| Arbutus Biopharma (ABUS) | 0.1 | $525k | NEW | 125k | 4.20 |
|
| Bridgebio Oncology Therapeut (BBOT) | 0.0 | $393k | NEW | 44k | 8.95 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.0 | $369k | NEW | 44k | 8.41 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.0 | $353k | NEW | 15k | 23.52 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.0 | $291k | -87% | 13k | 22.45 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.0 | $289k | -87% | 13k | 22.26 |
|
| Savara (SVRA) | 0.0 | $262k | NEW | 50k | 5.24 |
|
| Trevi Therapeutics (TRVI) | 0.0 | $92k | NEW | 6.7k | 13.76 |
|
| Trevi Therapeutics Com Cl A (TRVI) | 0.0 | $80k | NEW | 6.7k | 11.93 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2026 Q1 amended filed May 28, 2026
- Avidity Partners Management 2026 Q1 filed May 13, 2026
- Avidity Partners Management 2025 Q4 filed Feb. 13, 2026
- Avidity Partners Management 2025 Q3 filed Nov. 14, 2025
- Avidity Partners Management 2025 Q2 filed Aug. 14, 2025
- Avidity Partners Management 2025 Q1 filed May 15, 2025
- Avidity Partners Management 2024 Q4 filed Feb. 14, 2025
- Avidity Partners Management 2024 Q3 filed Nov. 14, 2024
- Avidity Partners Management 2024 Q2 filed Aug. 14, 2024
- Avidity Partners Management 2024 Q1 filed May 15, 2024
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022